These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 24507530)

  • 1. Clinical trials in multiple sclerosis.
    Cutter G; Kappos L
    Handb Clin Neurol; 2014; 122():445-53. PubMed ID: 24507530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcome measures in multiple sclerosis clinical trials.
    Andersson PB; Goodkin DE
    Baillieres Clin Neurol; 1997 Oct; 6(3):409-28. PubMed ID: 10101581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review of methodological issues of clinical trials in multiple sclerosis.
    Montalban X
    J Neurol Sci; 2011 Dec; 311 Suppl 1():S35-42. PubMed ID: 22206765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
    Lewis RJ; Lipsky AM; Berry DA
    Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bayesian approaches in medical device clinical trials: a discussion with examples in the regulatory setting.
    Bonangelino P; Irony T; Liang S; Li X; Mukhi V; Ruan S; Xu Y; Yang X; Wang C
    J Biopharm Stat; 2011 Sep; 21(5):938-53. PubMed ID: 21830924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A practical guide to Bayesian group sequential designs.
    Gsponer T; Gerber F; Bornkamp B; Ohlssen D; Vandemeulebroecke M; Schmidli H
    Pharm Stat; 2014; 13(1):71-80. PubMed ID: 24038922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paradigms for adaptive statistical information designs: practical experiences and strategies.
    Wang SJ; Hung HM; O'Neill R
    Stat Med; 2012 Nov; 31(25):3011-23. PubMed ID: 22927234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequentist performance of Bayesian inference with response-adaptive designs.
    Lecoutre B; Derzko G; Elqasyr K
    Stat Med; 2010 Dec; 29(30):3219-31. PubMed ID: 21170916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statistical designs for early phases of cancer clinical trials.
    Guan S
    J Biopharm Stat; 2012; 22(6):1109-26. PubMed ID: 23075011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MRI as an outcome in multiple sclerosis clinical trials.
    Daumer M; Neuhaus A; Morrissey S; Hintzen R; Ebers GC
    Neurology; 2009 Feb; 72(8):705-11. PubMed ID: 19073945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Bayesian approach to the statistical analysis of device preference studies.
    Fu H; Qu Y; Zhu B; Huster W
    Pharm Stat; 2012; 11(2):149-56. PubMed ID: 22374584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A framework for applying unfamiliar trial designs in studies of rare diseases.
    Gupta S; Faughnan ME; Tomlinson GA; Bayoumi AM
    J Clin Epidemiol; 2011 Oct; 64(10):1085-94. PubMed ID: 21530171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reconsidering clinical outcomes in Multiple Sclerosis: relapses, impairment, disability and beyond.
    D'Souza M; Kappos L; Czaplinski A
    J Neurol Sci; 2008 Nov; 274(1-2):76-9. PubMed ID: 18817932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical trials and rare diseases.
    Gerss JW; Köpcke W
    Adv Exp Med Biol; 2010; 686():173-90. PubMed ID: 20824446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Bayesian-frequentist two-stage single-arm phase II clinical trial design.
    Dong G; Shih WJ; Moore D; Quan H; Marcella S
    Stat Med; 2012 Aug; 31(19):2055-67. PubMed ID: 22415966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The quality of reports of randomized trials in multiple sclerosis: a review.
    Signori A; Baccino A; Sormani MP
    Mult Scler; 2012 Jun; 18(6):776-81. PubMed ID: 22495947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical trials in rheumatic diseases: designs and limitations.
    Pincus T; Sokka T
    Rheum Dis Clin North Am; 2004 Nov; 30(4):701-24, v-vi. PubMed ID: 15488689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Modern study designs and analysis methods in clinical research].
    Gerß J; Eveslage M; Faldum A; Schmidt R
    Z Rheumatol; 2015 Mar; 74(2):106-12. PubMed ID: 25805512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bayesian assessment of the influence and interaction conditions in multipopulation tailoring clinical trials.
    Millen BA; Dmitrienko A; Song G
    J Biopharm Stat; 2014; 24(1):94-109. PubMed ID: 24392980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic approaches to multiple sclerosis: an update on failed, interrupted, or inconclusive trials of neuroprotective and alternative treatment strategies.
    Meuth SG; Bittner S; Ulzheimer JC; Kleinschnitz C; Kieseier BC; Wiendl H
    BioDrugs; 2010 Oct; 24(5):317-30. PubMed ID: 20795753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.